FDA Accepts Supplemental NDA for Sotagliflozin by Lexicon Pharmaceuticals
The FDA has accepted the supplemental NDA for sotagliflozin (NDA216203) submitted by Lexicon Pharmaceuticals.
Therapeutic Area
Therapeutic area intelligence for SGLT-2 Inhibitor with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.